Navigation Links
Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
Date:8/20/2007

PITTSBURGHCarnegie Mellon University scientists have developed tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based drugs. The scientists created the nanogels using atom transfer radical polymerization (ATRP), which will ultimately enable the nanogels to deliver more drug directly to the target and to dispense the drug in a time-release manner.

The nanogels only 200 nanometers in diameter possess many unique properties that make them ideal drug-delivery tools, according to Daniel Siegwart, a graduate student in University Professor Krzysztof Matyjaszewskis laboratory at Carnegie Mellon. Siegwart will present his research Monday, Aug. 20 at the 234th national meeting of the American Chemical Society in Boston.

ATRP, a controlled living radical polymerization process, allows chemists to precisely regulate the composition and architecture of the polymers they are creating. Siegwart and colleagues used ATRP in inverse miniemulsion to make nanogels with a uniform network of cross-linked polymer chains within a spherical nanoparticle.

A uniform mesh size within the nanogels should improve the controlled release of the encapsulated drugs, said Siegwart. The major advance of this system is that ATRP allows one to prepare nanogels that are uniform in diameter. The size of the particles can be tuned, and we are currently investigating how nanogels of different sizes enter cells. The results may allow us to better understand the mechanism of endocytosis and to target specific tissues, such as cancer cells that have a more permeable membrane.

In their most recent advance, the Carnegie Mellon team incorporated the model carbohydrate drug rhodamine isothiocyanate-labeled dextran into the nanogels uniform mesh core. When the nanogels degraded, the model carbohydrate drug was released over time. The experiments were carried out with Jung Kwon Oh, a former postdoctoral associate in the Matyjaszewski lab who developed ATRP in inverse miniemulsion.

The new nanogels, which are nontoxic and biodegradable, can also accommodate molecules on their surfaces. During nanogel synthesis, the ATRP process allows scientists to incorporate targeting groups on the nanogel surface that can interact with specific receptors, such as those on the surface of a cancer cell. In addition, the nanogels can escape the notice of the bodys immune system, thus prolonging circulation time within the bloodstream.

The basic composition of the nanogels is based on an analogue of poly(ethylene oxide), a well-established biocompatible polymer that can enhance blood circulation time and prevent clearance by the reticuloendothelial system, the part of the immune system that engulfs and removes foreign objects from the body, said Siegwart.

In a recent article published in the Journal of the American Chemical Society, the Carnegie Mellon team demonstrated that its novel nanogels could be used to encapsulate doxorubicin, an anticancer drug. When the scientists mixed the doxorubicin-loaded nanogels with HeLa cancer cells in the laboratory, the doxorubicin was released, penetrating the cancer cells and significantly inhibiting their growth. They carried out this work in collaboration with Jeffrey Hollinger, professor of biomedical engineering and biological sciences and director of the Bone Tissue Engineering Center at Carnegie Mellon.


'/>"/>

Contact: Amy Pavlak
apavlak@andrew.cmu.edu
412-268-8619
Carnegie Mellon University
Source:Eurekalert

Related biology news :

1. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
2. Robot-based system developed at Carnegie Mellon detects life in Chiles Atacama desert
3. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
4. Carnegie Mellon University research reveals how cells process large genes
5. Carnegie Mellon cyLab researchers work to develop new red tide monitoring
6. Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace
7. Carnegie Mellon scientists create PNA molecule with potential to build nanodevices
8. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
9. Carnegie Mellon develops non-invasive technique to detect transplant rejection at cellular level
10. Carnegie Mellon scientists show brain uses optimal code for sound
11. DNA conclusive yet still controversial, Carnegie Mellon professor says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... SAN DIEGO , Feb. 23, 2017 /PRNewswire/ ... protein research tools, announced the acquisition of GenWay ... with a comprehensive service and product offering for ... "This acquisition will facilitate growth and enhance capabilities ... proteins, antibodies, and ELISA assays will nicely complement ...
(Date:2/22/2017)... 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics ... biopharmaceutical products for companion animals, will host a live conference ... to discuss financial results from the fourth quarter and full ... and investors may access the audio webcast or ... ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. ... be presenting at the Annual Biocom Global Life Science ... 2, at 11:15 AM, at the Torrey Pines Lodge, ... to the organizers at Biocom who have chosen our ... symposium of biotechnology companies, investors, and clinical researchers," said ...
(Date:2/22/2017)... ON (PRWEB) , ... February 22, 2017 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced it ... validate the ProMIS approach.” This is one of a series of commentaries from ...
Breaking Biology Technology: